Cigna Corp.

When the Federal Trade Commission (FTC) officially accused the three largest PBMs of artificially inflating insulin prices, it marked the latest move in what has become a protracted effort by federa

Ever since biosimilar competition to AbbVie Inc. 's Humira (adalimumab) began to hit the US market in early 2023, all eyes have been on the uptake of off-patent rivals, given that the product represe

AbbVie Inc. has enjoyed mainly plaudits for its handling of biosimilar competition to its top-seller, Humira (adalimumab), with its projections tracking close to reality since US biosimilars first en

Just as canaries once were used in coal mines to detect life-threatening levels of toxic gases before they sickened miners, Canary Speech is using vocal biomarkers to identify “previously silent healt